Adoptive immunotherapy with CD19 specific chimeric antigen receptor (CAR) T-cells has demonstrated dramatic success in the treatment of relapsed/refractory B-cell malignancies, with complete remission rates as high as 85% in patients with few to no therapeutic options available. This has led to FDA and Health Canada approval of two commercial grade CAR T-cell products. However, we remain in the early stages of development of this therapy with substantial clinical, scientific, and health economic questions to be addressed, such as how to decrease toxicity, improve response duration, and ensure just and equal access to all patients.